Application for Copanlisib/Rituximab Combo Submitted to FDA for Indolent NHL

Retrieved on: 2021-06-22 14:03:45

Tags for this article:

Click the tags to see associated articles and topics

Application for Copanlisib/Rituximab Combo Submitted to FDA for Indolent NHL. View article details on hiswai:

Excerpt

Bayer seeks FDA approval for its agent copanlisib in combination with rituximab for the treatment of patients with indolent non-Hodgkin lymphoma.

Article found on: www.cancernetwork.com